| News

Hemex attracts Swiss investors

11.02.2021

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The biotech incubator will use the funds to accelerate its global expansion.

Hemex, a Basel Area-based venture capitalist and incubator for biotech startups, has reported raising “a substantial amount” in an oversubscribed Series C financing round. According to a press release, the capital contribution was raised exclusively from a group of Swiss private investors.

Now, Hemex plans to use this money to hire “world-class talent” and accelerate its global expansion. The company wants to “invest in carefully selected startups” and deliver on its promise of “changing the future of healthcare”.

“We anticipate another year of strong growth for healthcare, both domestically and on a global level,” said Hemex CEO Pascal Winnen in the press release. “This vote of confidence for our business model from a group of successful entrepreneurs confirms that Hemex is on the right track for substantial future success.”

Hemex’s partners include the investment and innovation promotion agency Basel Area Business & Innovation and its DayOne Accelerator. Its portfolio includes Opterion Health AG, which announced at the end of January that it would be moving from the canton of Obwalden to the co-working space The 5th Floor in Muttenz. Basel Area Business & Innovation is providing support for the relocation.

In addition, Hemex has invested in Scailyte, a company based at the Novartis Campus of the Switzerland Innovation Park Basel Area. Support has also been provided to Resistell based in Muttenz, which claims to have made the world’s fastest antibiogram, and Basel cancer diagnostics expert Artidis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

BLKB supporting startups in Basel region
Basel Area Business & Innovation, Innovation

BLKB supporting startups in Basel region

Basellandschaftliche Kantonalbank (BLKB) has founded the inQbator startup accelerator. Together with its partners Hemex and Launchpad, the bank will be...

Read More
BioVersys receives funding in the fight against tuberculosis
Basel Area Business & Innovation, Invest

BioVersys receives funding in the fight against tuberculosis

The Basel-based pharma company BioVersys has received 2.7 million euros in funding alongside two partners. This financing serves to help...

Read More
Biosynex takes up residence in Delémont
Basel Area Business & Innovation, Invest

Biosynex takes up residence in Delémont

The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for COVID-19. It has...

Read More
Novartis Campus opening further
Basel Area Business & Innovation, Switzerland Innovation Park

Novartis Campus opening further

Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel...

Read More
docdok.health increases safety of coronavirus vaccinations
Basel Area Business & Innovation, Innovation

docdok.health increases safety of coronavirus vaccinations

The Basel-based start-up docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The...

Read More
Hemex attracts Swiss investors
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Hemex attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The...

Read More
1 2 3 40

Do you have a question? We'd like to hear from you.